Streetbeat News

Analyst Ratings

FFIN

Stephens & Co. analyst Matt Olney has maintained an Equal-Weight rating on First Finl Bankshares (NASDAQ:FFIN) and increased the price target from $30 to $32.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:01 pm

CFR

Stephens & Co. analyst Matt Olney has maintained an Equal-Weight rating on Cullen/Frost Bankers (NYSE:CFR) and increased the price target from $116 to $117.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:57 pm

GMS

Stephens & Co. analyst Trey Grooms has maintained an Overweight rating on GMS Inc. (NYSE:GMS) and increased the price target from $87 to $98.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:56 pm

WDC

Cantor Fitzgerald analyst C J Muse has reiterated an Overweight rating on Western Digital (NASDAQ:WDC) and maintained a $70 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:53 pm

KLAC

Cantor Fitzgerald analyst C J Muse has reiterated a Neutral rating on KLA Corporation (NASDAQ:KLAC) and maintained a price target of $625. The reaffirmation of the rating and price target suggests that the analyst believes the stock is fairly valued at its current level.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:50 pm

PTCT

Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on PTC Therapeutics (NASDAQ:PTCT) but reduced the price target from $51 to $45.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:42 pm

UNP

Benchmark analyst Nathan Martin has reiterated a Buy rating on Union Pacific (NYSE:UNP) and maintained a $260 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:34 pm

TMUS

Benchmark analyst Matthew Harrigan has reiterated a Buy rating on T-Mobile US (NASDAQ:TMUS) and maintained a $200 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:32 pm

INTC

Benchmark analyst Cody Acree has maintained a Buy rating on Intel Corporation (NASDAQ:INTC) and increased the price target from $52 to $62.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:30 pm

ALPN

Alpine Immune Sciences' stock (ALPN) is trading higher following an Outperform rating confirmation and a price target increase from $26 to $35 by Wedbush.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:28 pm